NDAs submitted to the FDA for the first oral GLP1 receptor agonist

NDAs submitted to the FDA for the first oral GLP-1 receptor agonist

Last month Novo Nordisk submitted two new drug applications (NDAs) to the FDA for its glucagon-like peptide-1 receptor agonist (GLP-1RA),...
Read More...

The post NDAs submitted to the FDA for the first oral GLP-1 receptor agonist appeared first on Pharmaceutical Technology.

Original Article: NDAs submitted to the FDA for the first oral GLP-1 receptor agonist

More From BioPortfolio on "NDAs submitted to the FDA for the first oral GLP-1 receptor agonist"